Similar trends were noted for patients with isolated other/unspecified VHD history, although reaching significance only for total (first and recurrent) HHF (HR, 2.54; 95% CI, 1.30-4.95; P < .01) and approaching significance for time to CV death.
← all excerpts
Safety and efficacy of empagliflozin in heart failure among patients with a history of valvular heart disease: Insights from EMPEROR-Pooled.
1
—
—